Zydus Cadila gets tentative nod from USFDA for cancer drug

Zydus Cadila gets tentative nod from USFDA for cancer drug

PTIUpdated: Tuesday, August 17, 2021, 06:43 PM IST
article-image
Zydus Cadila said the cancer drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad/ Representational image | File photo

Drug firm Zydus Cadila on Tuesday said it has received tentative approval from the US health regulator to market Lenalidomide capsules used for the treatment of various types of cancers.

The company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Lenalidomide capsules in the strengths of 2.5 mg, 5 mg,10 mg, 15 mg, 20 mg, and 25 mg, Zydus Cadila said in a statement.

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad, it added.

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders, the statement said.

The group now has 320 approvals and has so far filed over 400 abbreviated new drug applications (ANDAs) since the commencement of its filing process, it added.

Shares of Cadila Healthcare, the listed entity of the group closed at Rs 531.35 per scrip on BSE, down 0.10 percent from its previous close.

RECENT STORIES

Game-Changing Alliance: Ambani's Reliance Ventures Into Adani's Power For The First Time; Acquires...

Game-Changing Alliance: Ambani's Reliance Ventures Into Adani's Power For The First Time; Acquires...

SRM Contractors IPO Subscribed 86.57 Times On Last Day Of Bidding

SRM Contractors IPO Subscribed 86.57 Times On Last Day Of Bidding

Tax-Saving Tip From Zerodha CEO Nithin Kamath: 'If You're Married And Hindu..."; Here's How To Save...

Tax-Saving Tip From Zerodha CEO Nithin Kamath: 'If You're Married And Hindu...

Holy Cities Like Ayodhya, Varanasi Attracting Big Retail Brands: Report

Holy Cities Like Ayodhya, Varanasi Attracting Big Retail Brands: Report

A Big Relief For Byju's: NCLT Rejects Investor Plea To Stay Byju's Rights Issue EGM On March 29 Amid...

A Big Relief For Byju's: NCLT Rejects Investor Plea To Stay Byju's Rights Issue EGM On March 29 Amid...